Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 50,434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Gestational Trophoblastic Tumor
Interventions: pemetrexed disodium; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 25
States / cities: Birmingham, Alabama • Burbank, California • Orange, California + 19 more

Conditions: Terminal Care, Neoplasm
Interventions: End of life care coordination, FairCare System; Behavioral · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Albany, New York

Conditions: Metastatic Colorectal Carcinoma
Interventions: Observational; Other
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Interventions: NUV-1511; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more

Conditions: Lymphoma
Interventions: Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 76 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Distress screening; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Anaheim, California • Baldwin Park, California • Harbor City, California + 2 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Small Cell Lung Cancer
Interventions: cytology specimen collection procedure, laboratory biomarker analysis; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Myelogenous Leukemia, AML
Interventions: Venetoclax, Cytarabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 5
States / cities: Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Interventions: TYRA-300; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more

Conditions: Prostate Cancer
Interventions: Nexrutine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
Interventions: kisspeptin 112-121; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin, Thioguanine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound-Guided Biopsy; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 4
States / cities: Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas

Conditions: Leukemia, Lymphoma, Lymphoma, B-Cell
Interventions: CAR T-Cell Infusion; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Magnetic Resonance Imaging, Computed Tomography, Best Practice, Questionnaire Administration, Virtual Technology Intervention; Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumors
Interventions: BI 1703880, Ezabenlimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more

Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions: Divarasib, Sotorasib, Adagrasib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Kidney Cancer
Interventions: autologous tumor cell vaccine, keyhole limpet hemocyanin, therapeutic autologous dendritic cells, fludarabine phosphate, conventional surgery; Biological · Drug · Procedure
Lead sponsor: St. Luke's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer
Interventions: Acupuncture, Sham Acupuncture, Patient to receive standard care without Acupuncture or Sham Acupuncture.; Procedure · Other
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions: vapreotide, conventional surgery; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 18
States / cities: Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more

Conditions: Breast Cancer
Interventions: Accuboost APBI; Device
Lead sponsor: Brown University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: La Jolla, California • Lakeland, Florida • Providence, Rhode Island

Search by objective public record fields.

Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy

Effectiveness of the FairCare System for Patients With Advanced Illness

A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Implementing Systematic Distress Screening in Breast Cancer

Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients

Dampening the Reproductive Axis With Continuous Kisspeptin

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)